Results 151 to 160 of about 2,545,303 (281)

Early Experience With Evoque Transcatheter Tricuspid Valve Replacement in Carcinoid Heart Disease

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Tricuspid regurgitation (TR) is nearly universal in carcinoid heart disease (CHD), but surgical replacement carries significant risk, and CHD was excluded from the landmark TRISCEND II trial. We present seven patients with CHD undergoing Evoque transcatheter tricuspid valve replacement (TTVR) at two tertiary centers.
Jackson S. Burton, Ben Peterson, Brian Whisenant, Anwar Tandar   +3 more
wiley   +1 more source

Peri-Implant Diseases: The Past, the Present, the Future. [PDF]

J Periodontal Res
Berglundh T.
europepmc   +1 more source

Cangrelor Dosing, Administration, and Clinical Outcomes for Patients Undergoing Complex and High‐Risk Percutaneous Coronary Interventions

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Cangrelor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), with the advantage of rapid onset and offset. However, premature discontinuation may increase the risk of acute thrombosis for patients undergoing complex/high‐risk PCI (CHIP).
Siyu Ma, Wendy Y. Cheng, Yinong Liang, Josephine Bryar, Gwyneth Wei, Joshua D. Niznik, Christina Yin, Sue Liu‐Yi, Jimmy L. Kerrigan   +8 more
wiley   +1 more source

Patient- and implant-level factors associated with peri-implant diseases: a retrospective clinical and radiographic study of 968 implants. [PDF]

BMC Oral Health
Mashadiyev U, Gürkan İM, Gündoğar H, Özdemir H.   +3 more
europepmc   +1 more source

Bacterial Species Associated With Chronic Inflammation and Oral Cancer. A Comparative Study Between Patients With HNC and Patients With Chronic Periodontitis

Cancer Nexus, EarlyView.
ABSTRACT Objective To compare the presence and quantification of selected periodontopathogenic bacterial species and salivary parameters between patients with head and neck cancer (HNC) treated with radiotherapy and patients with chronic periodontitis, using chronic periodontitis as a reference model of oral dysbiosis.
Tanya Pereira‐Riveros, José López‐López, Alicia Lozano‐Borbalas, Julio Paciello‐Coronel, Teresa Vinuesa   +4 more
wiley   +1 more source

Effectiveness of Biomarker-Guided Implant Risk (BGIR) vs. IDRA and PiRA Scores in Predicting the Onset of Peri-Implant Diseases: A Long-Term Retrospective Study. [PDF]

J Clin Med
Guarnieri R, Reda R, Miccoli G, Cianfriglia M, Gherardi G, Testarelli L, Nardo DD.   +6 more
europepmc   +1 more source

Treatment of peri-implant disease : current knowledge

Peri-implant diseases represent serious complications after dental implant treatment, affecting both the surrounding soft and hard tissue. Regular, specific check-ups with the assessment and elimination of risk factors are effective precautions, and ...
Perez, Alexandre, Lombardi, Tommaso
core   +1 more source

From Policy Presence to Policy Performance: Adaptive Improvisation and the Everyday Politics of Plastic Burning Bans in Rural Indonesia

Environmental Policy and Governance, EarlyView.
ABSTRACT Open burning plastics is a major environmental health hazard in low‐ and middle‐income countries, releasing toxic pollutants and exacerbating climate change. Although Indonesia prohibits plastic burning, enforcement in rural settings remains fragile.
Sujarwoto Sujarwoto, Sekar Aqila Salsabila, Devita Rahmani Ratri, Asri Maharani   +3 more
wiley   +1 more source

The role of the oral microbiota and intrinsic host factors in peri-implant diseases: peri-implant mucositis versus peri-implantitis [PDF]

Aim: To characterize and compare the role of the oral microbiota and host biomarkers in patients with peri-implant mucositis and peri-implantitis. Methods: Patients diagnosed with either peri-implant mucositis (N=13) or peri-implantitis (N=20) were ...
Rozenblit, Amit
core  

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source